Treatment of hypercholesterolemia with statins;Statinbehandling av hyperkolesterolemi

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 22, 1997, Pages 3216-3220

  Erikssen, Jan ^a   Madsen, Steinar ^a  

^a Sentralsykehuset i Akershus ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; SHORT SURVEY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DRUG COSTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

EID: 0030870776     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (30)

1. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
2. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarland PW et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
5. Lambert M, Lupien P-J, Gagne C, Levy E, Blaichman S, Langlois S et al. and the Canadian Lovastatin in Children Study Group. Treatment of familial hypercholesterolemia in children and adolescents. Pediatrics 1996; 97: 619-28.
6. Knipscheer HC, Boelsen CCA, Kastelein JJP, van Dierman DE, Groenmeijer BE, Van Den Ende A et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867-71.
7. The Woscops Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 485-91.
8. Garnett WR. The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor. Clin Cardiol 1994; 17 (suppl IV): IV3-IV10.
9. Feussner G. HMG-CoA-reductase inhibitors. Curr Opin Lipidol 1994; 5: 59-68.
10. Tsuda Y, Staoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-33.
11. Kaczmarek D, Hohlfeld T, Wambach G, Schrör K. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolemia. A double-blind, placebo-controlled, prospective study. Eur J Clin Pharmacol 1993; 45: 4517-21.
12. Rubba P, Mancini M. Lipid lowering treatment: Effects on endothelial dysfunction. Curr Opin Lipidol 1995; 6: 348-53.
13. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelial-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-500.
14. van Boven AJ. Reduction of transient myocardial ischemia with pravastatin in addition to conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503-5.
15. Sheperd J. Fibrates and statins in the treatment of hyperlipidaemia: an apparisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13.
16. WHO Collaborating Centre for International Drug Monitoring. Adverse Reaction Newsletter 1993; 3: 1.
17. Buajordet I, Madsen S, Olsen H. Statiner - bivirkningsmonster med vekt på psykiske reaksjoner. Tidsskr Nor Lægeforen 1997; 117: 3210-3.
18. Wysowski DK, Gross TP. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med 1990; 150: 2169-72.
19. Newman TB, Hullery SB. Carcinogenecity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
20. Dalen JE, Dalton WS. Does lowering cholesterol cause cancer? JAMA 1996; 275: 67-9.
21. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A reappraisal. Drug Saf 1996; 91: 2488-96.
22. Berliner JA, Navab N, Fogelman AM, Frank JS, Demer LL, Edwards PA et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
23. Evans E. The French paradox: insights from international epidemiological studies. Lipid Review 1995; 9: 1-4.
24. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin J-L, Monjaud I et al. Mediterranen alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9.
25. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy middleaged Norwegian men. N Engl J Med 1993; 328: 5337-9.
26. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
27. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
28. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-802.
29. Jönnson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Eur Heart J 1996; 17: 1001-7.
30. Thorvik E, Aursnes I, Kristiansen IS, Waaler HT. Cost-effectiveness of cholesterol-lowering drugs: a review of the evidence. Wien Klin Wochenschr 1996: 108: 234-43.